In this issue:
- Decreasing higher energy foods/ portion sizes at worksite cafeterias
- Quantity/variety of food groups consumption and diabetes risk
- Efficacy of CGM on maternal and neonatal outcomes in GDM
- Effects of financial incentives and environmental strategies on weight loss
- Alcohol consumption and long-term type 2 diabetes risk after GDM
- SGLT-2 inhibitors vs. GLP agonists: CV outcome risk
- CSIIs vs. MDIs in emerging adults with type 1 diabetes
- Intranasal oxytocin: effects on food intake/craving
- Associations of BMI with cardiometabolic diseases
- Different effects of lifestyle intervention in high- and low-risk prediabetes
- Discontinuing CGM in type 2 diabetes treated with basal insulin
- Effects of empagliflozin on insulin therapy in type 2 diabetes with CV disease
- SGLT-2 vs. DPP-4 inhibitors in type 2 diabetes according to prior CV/kidney disease
- Glycaemic control in type 2 diabetes with high HbA1c at start of second-line therapy
Please login below to download this issue (PDF)